These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 29215037)

  • 1. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.
    Yang J; Guo X; Wang M; Ma X; Ye X; Lin P
    Sci Rep; 2017 Dec; 7(1):17166. PubMed ID: 29215037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy.
    Yang J; Xu H; Guo X; Zhang J; Ye X; Yang Y; Ma X
    Sci Rep; 2018 Feb; 8(1):3044. PubMed ID: 29445100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.
    Dogan E; Bozkurt O; Sakalar T; Derin S; Inanc M; Ozkan M
    J BUON; 2019; 24(5):1861-1869. PubMed ID: 31786848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer.
    Mercier J; Voutsadakis IA
    J Gastrointest Cancer; 2019 Sep; 50(3):493-506. PubMed ID: 29704170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of inflammation-based indexes in patients with stage III/IV colorectal cancer after adjuvant chemoradiotherapy.
    Yang J; Guo X; Wu T; Niu K; Ma X
    Medicine (Baltimore); 2019 Feb; 98(6):e14420. PubMed ID: 30732196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases.
    Neal CP; Cairns V; Jones MJ; Masood MM; Nana GR; Mann CD; Garcea G; Dennison AR
    Med Oncol; 2015 May; 32(5):144. PubMed ID: 25807934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.
    Sunakawa Y; Yang D; Cao S; Zhang W; Moran M; Astrow SH; Hsiang J; Stephens C; Tsuji A; Takahashi T; Tanioka H; Negoro Y; Takagane A; Tani S; Yamaguchi T; Eto T; Fujii M; Ichikawa W; Lenz HJ
    Clin Colorectal Cancer; 2018 Dec; 17(4):e741-e749. PubMed ID: 30219280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
    Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
    Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer.
    Passardi A; Scarpi E; Cavanna L; Dall'Agata M; Tassinari D; Leo S; Bernardini I; Gelsomino F; Tamberi S; Brandes AA; Tenti E; Vespignani R; Frassineti GL; Amadori D; De Giorgi U
    Oncotarget; 2016 May; 7(22):33210-9. PubMed ID: 27120807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer.
    Cruz-Ramos M; Del Puerto-Nevado L; Zheng B; López-Bajo R; Cebrian A; Rodríguez-Remirez M; García-García L; Solanes-Casado S; García-Foncillas J
    J Geriatr Oncol; 2019 Sep; 10(5):742-748. PubMed ID: 30327283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients.
    Holub K; Biete A
    Clin Transl Oncol; 2019 Jul; 21(7):836-844. PubMed ID: 30470994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
    World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematologic Markers of Lung Metastasis in Stage IV Colorectal Cancer.
    Abu-Shawer M; Abu-Shawer O; Souleiman M; Akkawi M; Alshakhatreh O; Altamimi T; Al-Omari A; Al-Hussaini M
    J Gastrointest Cancer; 2019 Sep; 50(3):428-433. PubMed ID: 29589285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
    Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
    Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor.
    Neofytou K; Smyth EC; Giakoustidis A; Khan AZ; Cunningham D; Mudan S
    Med Oncol; 2014 Oct; 31(10):239. PubMed ID: 25218270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
    Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M;
    BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.